More then 90+ years of experience in our team.
More then 90+ years of experience in our team.
CTC Netherlands specializes in early-phase (Phase 1/2a) trials, focusing on safety, pharmacokinetics, and efficacy. Located at UMCG, it utilizes advanced technology and collaborates with specialized departments, supporting complex studies with both patients and healthy volunteers, including CSF sampling and PET/MRI imaging.
Proof of Concept Studies: Focusing on the clinical conduct of Phase 1/2a trials, we design and implement studies to evaluate the initial efficacy and feasibility of new treatments, bridging the gap between preclinical research and clinical application.
Early Phase Patient Studies: Specializing in Phase 1/2a trials, we conduct early-stage clinical studies with patient populations to assess safety, optimal dosing, and preliminary effectiveness, providing a critical foundation for further development.
Specialized Healthy Volunteer Studies: Our expertise includes conducting complex, invasive Phase 1/2a studies with healthy volunteers, utilizing advanced procedures such as continuous cerebrospinal fluid (CSF) sampling, PET and MRI imaging, EEGs, and DEXA scans. These capabilities enable us to capture high-quality, detailed data essential for early-stage insights in clinical research.
Integrated Location and Collaborations: Located on the premises of a large teaching hospital, we have established strong relationships with key research departments, including neurology, geriatrics, urology, anesthesiology, psychiatry, internal medicine, and clinical pharmacology. This integration enhances our access to specialized knowledge and resources, fostering a collaborative environment for conducting complex, multi-disciplinary studies.
Our facility is a hospital-based, fully equipped Clinical Site, designed to support a full range of early-phase clinical trials within a safe, well-resourced environment. Located on the premises of the University Medical Center Groningen (UMCG), we benefit from direct access to one of the Netherlands’ largest and most renowned teaching hospitals. UMCG is a leader in both clinical care and medical research, particularly in areas such as neuroscience, oncology, and complex genetic and chronic conditions. This partnership enhances our access to cutting-edge technology, medical expertise, and an extensive network of specialized research departments.
Key features of our facility include:
Our dedicated Clinical Site combines comfort, advanced monitoring, and immediate hospital support, creating an ideal setting for conducting early-phase clinical research with optimal safety and care.
In addition to the experienced team at CTC Netherlands, we collaborate with three renowned clinical pharmacology experts, each with an impressive track record:
This network strengthens our ability to deliver high-quality outcomes in complex clinical studies.
In collaboration with Prof. Dr. T. (Teus) van Laar, Professor of Neurology, our research focuses on advanced treatment strategies for Parkinson’s disease. We have access to a comprehensive database of nearly 5,000 Parkinson’s disease (PD) patients, with genotyping data available for over 500 individuals. Our work targets genetic variations in key genes associated with Parkinson’s pathology, including SNCA, LRRK2, GBA1, PRKN, PINK1, and DJ-1. This data facilitates research into the genetic factors influencing disease progression and treatment outcomes, enabling potential personalized approaches in PD management.
In the field of psychiatry, we work closely with Prof. Dr. R.A. (Robert) Schoevers, Professor and Head of the Psychiatry Department, who brings extensive experience and interest in conducting studies involving psychedelics. Prof. Schoevers is also a key figure in Psynapse, a nationwide consortium in the Netherlands dedicated to advancing clinical research in psychiatric patients. This collaboration supports our research into novel psychiatric treatments and the development of evidence-based approaches for patients with complex psychiatric conditions.
Located on the UMCG campus, our research network offers access to over 30 specialized research departments, allowing for interdisciplinary studies in rare and complex diseases. This is complemented by collaborations with 7 academic hospitals and 26 top clinical hospitals across the Netherlands, providing a broad platform for comprehensive clinical research and trial access.
At our clinical site, the safety and well-being of research participants are our highest priorities. We have rigorous protocols and a highly trained team in place to ensure that every study is conducted with the utmost care and responsibility.
Through these measures, we are committed to maintaining a safe, controlled environment that prioritizes participant safety at every stage of the research process.
CTC stands out by its in-house Site Network with an state-of-the-art research clinic in the middle of Groningen. We provide full-service management and conduct of Phase 0, FIH, Phase I and Phase II studies as well as medical device investigations. Our site network supports clinical trials in all phases of development.